Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine

The RV144 vaccine trial showed reduced risk of HIV-1 acquisition, but mechanisms underlying protection are poorly understood. Here, Fourati et al. assess the transcriptomic profile of blood collected from 223 vaccinees and 40 placebo recipients and identify IRF7 as a mediator of protection.

Bibliografiska uppgifter

Huvudupphov:	Slim Fourati, Susan Pereira Ribeiro, Filipa Blasco Tavares Pereira Lopes, Aarthi Talla, Francois Lefebvre, Mark Cameron, J. Kaewkungwal, P. Pitisuttithum, S. Nitayaphan, S. Rerks-Ngarm, Jerome H. Kim, Rasmi Thomas, Peter B. Gilbert, Georgia D. Tomaras, Richard A. Koup, Nelson L. Michael, M. Juliana McElrath, Raphael Gottardo, Rafick-Pierre Sékaly
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Nature Portfolio 2019-02-01
Serie:	Nature Communications
Länkar:	https://doi.org/10.1038/s41467-019-08854-2
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!